GlassScriptPhysician profile
Tanima Jana
NPI 1730434648
$2,161.22
in general payments reported to CMS, 2019-2025
14 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $238 · 2020: $49.96 · 2021: $325 · 2022: $431 · 2023: $325 · 2024: $451 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $489.64 | 2022-2025 | Conmed Biliary, Conmed Generators |
| Boston Scientific Corporation | $450.87 | 2019-2024 | X-Tack Endoscopic Helix Tacking System |
| Apollo Endosurgery US INC | $234.38 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $215.25 | 2023-2024 | Dupixent |
| Medtronic, INC. | $177.56 | 2025 | Beacon, Endoflip |
| 3-D Matrix, INC. | $173.57 | 2024 | |
| Abbvie INC. | $121.23 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $103.66 | 2019 | |
| Erbe USA INC | $54.93 | 2021 | |
| Pfizer INC. | $53.25 | 2023 | |
| Ambu INC. | $36.62 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.45 | 2023 | Xifaxan |
| Pentax of America, INC. | $17.40 | 2022 | |
| Qol Medical, LLC | $14.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanima Jana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.